CHICAGO --(BUSINESS WIRE)--Feb. 18, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous
CHICAGO --(BUSINESS WIRE)--Feb. 12, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s proprietary eyonis® LCS to the Tempus Pixel platform.
CHICAGO --(BUSINESS WIRE)--Feb. 10, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026.
CHICAGO --(BUSINESS WIRE)--Jan. 27, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes
Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital pathology CHICAGO --(BUSINESS WIRE)--Jan. 21, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today
CHICAGO --(BUSINESS WIRE)--Jan. 12, 2026-- Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health , one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration aimed at transforming cancer care through advanced
Collaboration will focus on the oncology patient population CHICAGO --(BUSINESS WIRE)--Jan. 12, 2026-- Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients.
Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38% 2025 Net revenue retention of ~126% CHICAGO --(BUSINESS WIRE)--Jan. 11, 2026-- Tempus AI, Inc.
CHICAGO --(BUSINESS WIRE)--Jan. 11, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025 .
CHICAGO --(BUSINESS WIRE)--Jan. 8, 2026-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO ® Gastrointestinal Cancers Symposium.
